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                                                  ABSTRACT 
 
 
 
BACKGROUND AND OBJECTIVES 
 
 
Type 2 diabetes mellitus is associated with the development of premature 
atherosclerosis and a higher cardiovascular morbidity and mortality. Diabetic 
dyslipidaemia is believed to play an important role in the pathogenesis of 
accelerated atherosclerosis in this condition. It is being increasingly believed 
that atherosclerosis is a postprandial phenomenon as at least with respect to 
lipids, we are in the postprandial phase for most of the day. High postprandial 
triglycerides have shown a strong and independent association with CAD. 
Hence this study is being carried out to assess the characteristics of post 
prandial dyslipidaemia in types 2 diabetes mellitus in comparison with the 
fasting lipid levels in diabetics and controls. 
 
 
METHODOLOGY 
 
 
This was an observational study which included the patients admitted in 
The Government Mohan kumaramangalam Medical college Hospital, Tamil 
Nadu. The study included 50 patients with type 2 diabetes mellitus meeting the 
inclusion criteria and were compared with 50 age and sex matched healthy 
controls, fulfilling the inclusion and exclusion criteria. 
18 
 
METHOD OF COLLECTION OF DATA 
 
 
Data for the proposed study was collected in a pretested proforma . 
Detailed history and physical examination of all the cases and controls was 
done.  Fasting and Post prandial lipid levels were estimated in all the cases and 
controls. Blood was collected from patients after an overnight (12-hour) fast and 
six hour postprandial (after a standard meal) for lipid profile measurements. 
 
RESULTS 
 
 
The majority of cases and controls were in the age group of 61-70 years.   
All the cases in the fasting state had a raised triglyceride (mean 
172.92±75.51mg/dL) level, raised VLDL-C (mean 37.76±20.01mg/dL) level, 
decreased HDL-C (mean 33.44±11.99mg/dL) level, normal total cholesterol 
(mean 176.36±52.43mg/dL) level and normal LDL-C (mean 
101.16±38.17mg/dL) levels compared to the control group. 
 
In the post prandial state the diabetics had a significant increase in the 
post prandial triglyceride level (mean 232.52±105.08mg/dL), decrease in the 
HDL-C level (mean 30.96±11.15mg/dL)  compared to the fasting state whereas 
in the control group there was no significant increase in the post prandial lipid 
levels compared to the fasting state. 
19 
 
CONCLUSION 
 
The dyslipidemia of Type 2 DM is characterised mainly of raised 
triglyceride levels, raised VLDL-C Levels and decreased HDL-C levels. In the 
post prandial state there was significant hyper-triglyceridaemia and decreased 
HDL-C level in diabetics when compared to that of the controls. 
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   INTRODUCTION 
 
Diabetes mellitus (DM) refers to a group of common metabolic disorders  
characterised  by the distinct  phenotype of  hyperglycemia.  Various  distinct  
types of DM are due to the complex interaction of  the environmental and the  
genetic  factors.
 
 
 
Based on the etiology of the DM,  factors responsible for hyperglycemia 
 
are reduced insulin secretion,  decreased glucose utilization,  and increased 
 
glucose production. The metabolic dysregulation seen in DM is responsible 
 
for 
secondary pathophysiologic changes in multiple organ systems which results 
 
in  
tremendous burden on the individual suffering from diabetes  as well as on 
 
the 
health care system. 
 
 
DM is classified based on the  the pathogenic process responsible for 
hyperglycemia, as opposed to earlier criteria based on age of onset or type of 
therapy.  
The two broad categories of  DM are designated as  type 1diabetes  and 
type 2 diabetes. Both  types of diabetes are preceded by the period of abnormal 
glucose homeostasis . Type 1 DM occurs because of  complete or near-total 
insulin deficiency. Type 2 DM is a heterogeneous group of disorders and the 
21 
 
factors responsible for hyperglycemia include  variable degrees of insulin 
resistance, impaired insulin  secretion, and increased glucose production. 
Distinct genetic and metabolic  defects in insulin action and/or secretion is 
responsible for the common phenotype of  hyperglycemia in type 2 DM and 
have important potential therapeutic implications based on which the 
pharmacologic agents are available to target specific  metabolic derangements.  
Type 2 DM is preceded by a phase of abnormal  glucose homeostasis defined as 
impaired fasting glucose (IFG) or impaired  glucose tolerance (IGT).
 
 
Dyslipidemia that is associated with  type 2 diabetes  plays a vital role in  
the pathogenesis of accelerated atherosclerosis in that population.
 
 The  most 
important features of this dyslipidemia include  an elevated very low  density 
lipoproteins (VLDL) and total triglycerides (TGs) and a decreased high  density 
lipoproteins (HDL) concentration in the serum. While fasting 
hypertriglyceridemia plays an important role in  atherosclerosis, particularly in 
people with  diabetes mellitus, 
 
this  association has been less consistent and 
fasting HDL-C appears to be a far more significant determinant of 
atherosclerosis.
 
However, when TGs are analysed in  the postprandial state,  
they emerge as an independent and stronger coronary  risk factors than  HDL-C. 
 
 
 
22 
 
Postprandial hypertriglyceridemia is shown to be associated with  asymptomatic  
and symptomatic macro vascular disease in both normo- and  
hypertriglyceridemic  groups  and such abnormalities have been  reported in 
people with type 2 diabetes and hence 
 
the increased risk of  atherosclerosis 
among them,  might  therefore be correlated to the higher degree  of 
postprandial triglyceridemia.  
 
Earlier studies clearly demonstrate the presence of  hypertriglyceridemia in  the 
postprandial state  among the diabetic subjects,  irrespective of  whether  fasting  
triglyceride levels were high or low. 
 
It is not clearly known whether the patients with type 2 diabetes with macro  
vascular disease  have greater abnormalities of  the  triglyceride  metabolism  in  
the post prandial state than those without. 
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                          AIMS AND OBJECTIVES 
 
 
1. To study the post-prandial lipid abnormalities in patients with type 2 
Diabetes Mellitus. 
 
 
2. To compare the relationship between fasting and post-prandial lipids in 
Diabetics and Non Diabetics  
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         REVIEW OF LITERATURE 
The worldwide prevalence of DM has risen dramatically over the past two 
decades, from an estimated 30 million cases in 1985 to 382 million in 2013. 
Based on the current trends, the International Diabetes Federation projects that 
592 million will have diabetes by 2035. Although the prevalence of both type 1 
and type 2 DM is increasing worldwide, the prevalence of type 2 DM is rising 
much more rapidly, presumably because of increasing obesity, reduced activity 
levels as countries become more industrialized, and the ageing of the 
population.
(1) 
 
In 2013, the prevalence of diabetes in individuals from age 20-79 ranged 
from 23 to 37% in the 10 countries with highest prevalence. The countries with 
the greatest number of individuals with diabetes in 2013 are China ( 98.4 
million), India (65.1 million), United States (24.4 million), Brazil (11.9 million) 
and the Russian federation (10.9 Million). DM increases with aging. In 2012, 
the prevalence of DM in the United States was estimated to be 0.2% in 
individuals aged <20 years and 12% in individuals aged >20 years. In 
individuals aged >65 years, the prevalence of DM was 26.9%. The prevalence is 
similar in men and women throughout most age ranges.
(1) 
25 
 
 
 
                      Fig. 1  Worldwide  Prevalence of diabetes in 2013 
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                        LIPIDS AND LIPOPROTEINS 
 
The lipids are a heterogeneous group of compounds that are important dietary 
constituents not only because of their high energy value, but also because of the 
fat-soluble vitamins and the essential fatty acids contained in the fat of natural 
foods. 
1 
 
They are found in cell membranes, which maintain cellular integrity and allow 
the cytoplasm to be compartmentalized into specific organelles. Lipids function 
as a major form of stored nutrients (triglycerides), as precursors of adrenal and 
gonadal steroids and bile acids (cholesterol), and as extracellular and 
intracellular  messengers (e.g., prostaglandins, phosphatidylinositol). 
2 
  
Combinations of lipid and protein (lipoproteins) are important cellular 
constituents, occurring both in the cell membrane and in the mitochondria, and 
serving also as the means of transporting lipids in the blood. 
1
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Classification of lipids 
1 
 
1. Simple lipids: Esters of fatty acids with various alcohols.                                                  
a. Fats: fatty acids + glycerol 
b. Waxes: fatty acids + higher molecular weight monohydric alcohols 
 
2. Complex lipids: Esters of fatty acids containing groups in addition to an   
     alcohol and a fatty acid. 
a. Phospholipids: fatty acids + alcohol + a phosphoric acid residue. 
Eg. glycerophospholipids , sphingophospholipids 
b. Glycolipids (glycosphingolipids): Lipids containing a fatty acid, 
sphingosine, and carbohydrate. 
c. Other complex lipids: eg. Sulfolipids, aminolipids, Lipoproteins. 
 
3 . Precursor and derived lipids: These include fatty acids, glycerol, steroids,               
    other alcohols, fatty aldehydes, and ketone bodies , hydrocarbons, lipid-  
     soluble vitamins, and hormones. 
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                              LIPOPROTEINS 
 
Lipoproteins are microemulsions composed of lipids (cholesterol, cholesteryl 
ester, triglyceride, and phospholipid) and proteins (apoproteins). Their function 
is to transport non-water-soluble cholesterol and triglycerides in plasma. 
3,4,5 
 
Structure of a plasma lipoprotein. 
1 
Lipoproteins consist of a nonpolar lipid core made up of mainly triacylglycerol 
and cholesteryl ester and is surrounded by a single surface layer of amphipathic 
phospholipid and cholesterol molecules. The protein moiety of a lipoprotein is 
known as an apolipoprotein or apoprotein. 
Apolipoproteins carry out several roles: 
(1) They can form part of the structure of the lipoprotein, 
(2) They are enzyme cofactors, and 
(3) They act as ligands for interaction with lipoprotein receptors in tissues. 
 
29 
 
 
 
 
            Fig. 2 : Structure of a plasma lipoprotein 
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Classification 
3 
 
Lipoproteins have been classified on the basis of their densities during 
ultracentrifugation. 
 
Fig. 3 : Classification of plasma lipoproteins 
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Table 1 : Major classes of plasma lipoproteins 2 
 
Type 
Density Electrophoretic Site of Major Lipids Major 
 
 
 
 
(g/mL) Mobility Origin Apolipoproteins    
 
Chylomicrons < 0.95 Origin Intestine 85% B48, AI, AIV (E, 
 
    Triglyceride CI, CII, CIII—by 
 
     transfer from 
 
     HDL)   
 
        
 
Chylomicron <1.006 Origin Intestine 60% B48, E   
 
Remnants    Triglyceride,    
 
    20% cholesterol    
 
        
 
    55%    
 
    Triglyceride, B100, E, CI, CII, 
 
VLDL <1.006 Pre-β Liver 20% cholesterol CIII   
 
        
 
   Derived     
 
IDL 
1.006- 
Β 
from 35% Cholesterol, 
B100, E 
  
 
1.019 VLDL 25% triglyceride   
 
        
 
LDL 1.019- Β Derived 60% Cholesterol, B100   
 
 1.063  from IDL 5% triglyceride    
 
        
 
HDL 1.063- Α Liver, 25% AI,  AII, CI, CII, 
 
 1.21  intestine, Phospholipid, CIII, E   
 
   plasma 20% cholesterol,    
 
    5% triglyceride    
 
    (50% protein)    
 
       
 
Lp(a) 1.05- Α Liver 60% Cholesterol, B100, apo(a)  
 
 1.09   5% triglyceride    
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                           LIPOPROTEIN METABOLISM 
 
Chylomicrons : 
Chylomicrons are the largest of the plasma lipoproteins and  
are composed of 98% to 99% lipid (85%-90% triglyceride) and 1% to 2% 
protein. They contain several apolipoproteins, including apo-B48, apo-AI,     
apo-AIV, apo-E, and the C apolipoproteins . 
6, 7, 8 
 
Origin :  
Chylomicrons are produced by the epithelial cells of the small intestine 
(duodenum and proximal jejunum) when dietary fat and cholesterol are 
presented to the brush border of the epithelial cell membranes as bile acid 
micelles. Triglycerides, phospholipids, and cholesterol (absorbed or synthesized 
by the intestinal cells) are used for chylomicron formation in the Golgi 
apparatus, where some of the apolipoproteins undergo final carbohydrate 
processing, and the chylomicrons are secreted into the space along the lateral 
borders of the intestinal cells. From there, they enter the mesenteric lymph and 
proceed through the thoracic duct lymph to the general circulation. Newly 
synthesized chylomicrons possess apo-B48, apo-AI, and 
apo-AIV (intestinally synthesized apolipoproteins); they acquire apo-E and       
C apolipoproteins in the lymph and blood, primarily from HDL. 
2
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Metabolic Fate :   
In the circulation, LPL catalyzes the release of  FFAs from 
chylomicron triglycerides and converts them into triglyceride-poor, cholesterol 
enriched chylomicron remnants. Chylomicron remnants are cleared rapidly 
from the plasma by the liver. 
9, 10, 11 
 
Function : Major carrier of exogenous (dietary) triglycerides. 
1 
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Figure 4 :  General scheme summarizing the major pathways involved  in 
the metabolism of chylomicrons synthesized by the intestine  and VLDL 
synthesized by the liver. 12
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Very-Low-Density Lipoproteins 
 
Characteristics : VLDLs  are made up of 85% to 90% lipid (about 55% 
triglyceride, 20% cholesterol, and 15% phospholipid) and 10% to 15% protein. 
The distinctive apolipoprotein is apo-B100, the hepatic form of apo-B. VLDLs 
also contain apo-E and C apolipoproteins. 
6, 13
 
 
Origin : VLDLs are synthesized by the liver, and their production is stimulated 
by increased delivery of FFAs to the hepatocytes, either from a high intake of 
dietary fat or from the mobilization of fatty acids from adipose tissue with 
fasting or uncontrolled diabetes mellitus. Triglycerides and phospholipids to be 
used in the formation of VLDL are synthesized in the liver, whereas VLDL 
cholesterol can be synthesized de novo or reused from LDL cholesterol. 
14 
 
Metabolic Fate : VLDL triglycerides are hydrolyzed by the actions of LPL and 
hepatic lipase. They are converted to smaller and smaller particles that become 
increasingly rich in cholesterol. The products of VLDL catabolism are IDLs. 
IDLs are processed to LDLs.
2 
Approximately half of VLDLs are converted to LDLs, and the remainder are 
cleared directly by the liver as VLDL remnants (small VLDL) and IDLs.
 15, 16, 17 
Function : Major carrier of endogenous triglycerides. 
1 
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Intermediate-Density Lipoproteins 
 
Characteristics : IDLs are normally present in low 
concentrations in the plasma and are intermediate in size and composition 
between VLDL and LDL. Their primary proteins are apo-B100 and apo-E. 
13, 15 
 
Metabolic fate : They are precursors of LDLs and represent metabolic products 
of VLDL catabolism in the plasma by the action of lipases. IDLs may be further 
processed by hepatic lipase or removed from the plasma by the LDL receptor.
2 
 
Function : IDLs are often considered to be VLDL remnants and to be 
atherogenic. 
2 
 
Low-Density Lipoproteins 
 
Characteristics : LDLs  are the major cholesterol-carrying lipoproteins in the 
plasma; about 70% of total plasma cholesterol is in LDL. LDLs are composed 
of approximately 75% lipid (about 35% cholesteryl ester, 10% free cholesterol, 
10% triglyceride, and 20% phospholipid) and 25% protein. Apo-B100 is the 
principal protein in these particles, along with trace amounts of apo-E. 
13, 18
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Origin : LDLs are the end products of lipase-mediated hydrolysis of VLDLs. 
2 
 
Metabolic Fate : About 75% of LDL is taken up by hepatocytes. Other tissues 
take up smaller amounts of LDL. Approximately two thirds of the uptake is 
mediated by the LDL receptor, and the remainder is mediated by a poorly 
defined process that does not involve receptors. LDLs are considered to be 
atherogenic. 
2 
 
Function : Transports cholesterol from liver to peripheral tissues. 
2 
 
High-Density Lipoproteins 
 
Characteristics : HDLs are small particles (70-120 Å in diameter) which 
contain about 50% lipid (25% phospholipid, 15% cholesteryl ester, 5% 
free cholesterol, and 5% triglyceride) and 50% protein. Their major 
apolipoproteins are apo-AI (65%), apo-AII (25%), and smaller amounts of the C 
apolipoproteins and apo-E . Apo-E is a minor component of a subclass of HDL 
referred to as HDL1. HDLs serve as a reservoir for apo-E and the C 
apolipoproteins to be distributed to other lipoproteins when they enter the 
plasma (e.g., chylomicrons, VLDLs). 
18, 19, 20 
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They are divided into two major subclasses : 
1. HDL2 (d = 1.063-1.125 g/mL) 
2. HDL3 (d = 1.125-1.21 g/mL). 
 
Origin : HDLs originate from three major sources. 
1. The liver secretes an apo-AI-phospholipid disc called nascent or precursor 
HDL (pre-β HDL). 
2. The intestine directly synthesizes a small apo-AI–containing HDL particle. 
3. HDLs are derived from surface material (primarily apo-AI and phospholipid) 
that comes from chylomicrons and VLDLs during lipolysis. 
 
Maturation of High-Density Lipoproteins. 
19, 20 
 
The nascent or precursor HDL particles exist as apo-AI-phospholipid discs. 
Designated pre-β1, pre-β2, and pre-β3, these discs are excellent acceptors of 
free cholesterol from cells with excess cholesterol or from other lipoproteins 
forming small, spherical, mature HDL particles (HDL3) . (HDL3) accepts more 
free cholesterol and increases in size, forming HDL2. 
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HDL1 can also arise from a precursor particle that displays γ-electrophoretic 
mobility and is called γLp-E. This particle is approximately 80% protein and 
20% lipid (primarily sphingomyelin and phosphatidylcholine, with some free 
cholesterol). The γLp-E is a good acceptor of free cholesterol from cells and 
appears to be converted to the larger HDL1. 
 
Function : Is a main transporter of cholesterol from peripheral tissue to liver. 
 
Acquisition of Cholesterol by High-Density Lipoproteins 
HDL, especially HDL3, precursors of mature HDL, and lipid-poor apo-AI, can 
acquire cholesterol from cells by two mechanisms. aqueous transfer from cells 
and transport facilitated by a cell-surface binding protein. 
21, 22 
 
Metabolic Pathways Involving High-Density Lipoproteins 
 
HDLs function in the redistribution of lipids among lipoproteins and cells by a 
process called reverse cholesterol transport. 
19, 20, 22 
HDLs acquire cholesterol from cells and transport it to the liver for excretion or 
to other cells that require cholesterol. The scheme is shown in Fig. 4. 
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Figure 5 :
 2 
Role of high-density lipoprotein (HDL) in the redistribution   of 
Lipids from cells with excess cholesterol to cells requiring cholesterol or to 
the liver  for excretion.  
   
 
41 
 
A second pathway of cholesterol redistribution involves CETP  ( Fig. 4) CETP 
transfers cholesteryl ester from HDL2 to VLDL, IDL, LDL, and remnants. The 
cholesterol is thus delivered indirectly to the liver through VLDL and 
chylomicron remnant pathways. In exchange for transfer of the cholesteryl 
ester, CETP transfers triglyceride from VLDL, IDL, LDL, and remnants to 
HDL2, which becomes enriched with triglycerides. The CETP pathway is the 
major route for the transport and delivery of cholesteryl esters from HDL to the 
liver in humans. 
23, 24
 
 
A third pathway involves SR-BI ( Fig. 4). Cholesteryl esters are removed from 
the particle by selective uptake and preferentially delivered to the liver, adrenal 
glands, and gonads. The SR-BI can facilitate the transfer of cholesteryl esters 
from HDL to cells without the lipoprotein particle's entering the cell or being 
degraded. The SR-BI appears to function by transferring cholesteryl ester 
through a hydrophilic channel formed in the cell membrane. 
25
 
 
HDL2 Is Reconverted to HDL3 to Regenerate These Cholesterol Acceptors. 
26 
HDL2 particles are partially depleted of cholesteryl esters and enriched in 
triglycerides by the action of CETP. Hepatic lipase can then act on the large, 
triglyceride-enriched HDL2 to hydrolyze the triglycerides (and possibly excess 
phospholipids), converting HDL2 to HDL3. HDL3 serves as an acceptor of free 
cholesterol, thus perpetuating the HDL2-HDL3 cycle (Fig 4) 
42 
 
High-Density Lipoproteins as Anti-atherogenic Lipoproteins 
 
Numerous studies have demonstrated that high levels of HDL-C are associated 
with a lower incidence of CHD. Conversely, low levels of HDL-C are 
associated with a higher incidence of CHD.
27
 The protective mechanism 
involving HDL may be related to its role in reverse cholesterol transport, which 
results in redistribution of cholesterol away from the artery wall. Other 
potentially protective roles for HDL include inhibition of monocyte adhesion 
and antioxidative activity that could prevent LDL oxidation. 
2 
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           LIPOPROTEIN ALTERATIONS IN TYPE2 DIABETES
 
 
Table 2 : Lipoprotein alterations in type 2 diabetes. 
3 
Lipoprotein Alterations 
  
                Increased production of triglyceride and apoB, 
 
 
Decreased clearance of triglyceride and apoB, 
VLDL ↑  
 Abnormal composition 
                  
  
 Increased production of LDL apoB, 
 Decreased receptor-mediated clearance, 
 Triglyceride enrichment, 
LDL ↑→ Smaller (more dense) particle distribution, 
 Glycation, 
 Oxidation 
  
 Increased clearance of apoA, 
 Decreased proportion of large HDL, 
 Triglyceride enrichment, 
HDL ↓ Glycation, 
 Diminished reverse cholesterol transport 
  
Chylomicron Delayed clearance; remnant accumulation 
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Alterations in Triglycerides and VLDL 
 
The most common alteration of lipoproteins in type 2 diabetes is 
hypertriglyceridemia caused by an elevation in VLDL concentrations. It is clear, 
however, from population-based studies
28, 29 
 that type 2 diabetes generally is 
associated with only a 50% to 100% elevation in the plasma levels of total and 
VLDL triglycerides. Thus, it is likely that subjects with type 2 diabetes who 
have concentrations of total triglycerides greater than 350 to 400 mg/dL also 
have genetic defects in lipoprotein metabolism, the expression of which may be 
exacerbated by hyperglycemia. 
30
 
 
Metabolic Determinant 
One of the determinants of diabetic hypertriglyceridemia is the overproduction 
of VLDL triglyceride, which is most likely due to the increased flow of 
substrates, particularly glucose and free fatty acids, to the liver. In addition, 
individuals with type2 diabetes appear to have a defect in clearance of VLDL 
triglyceride that parallels the degree of hyperglycemia. Overproduction of 
VLDL apoB and decreased fractional catabolic rate for VLDL apoB also occurs 
in type 2 diabetes. 
31, 32, 33 
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The alterations in VLDL metabolism in type 2 diabetes are related in part to 
insulin resistance. Hyperinsulinemia and the central obesity that typically 
accompanies insulin resistance also are thought to lead to overproduction and 
impaired catabolism of VLDL. 
In addition to increases in the amount of VLDL, individuals with diabetes, 
especially those with severe hyperglycemia, may have larger triglyceride-rich 
VLDL. Subfractions of VLDL have been found to be enriched in the proportion 
of cholesterol-rich particles. These compositional changes may have 
implications for the increased propensity for atherosclerosis among people with 
type 2 diabetes, because cholesterol-enriched VLDL may be atherogenic.
35, 36 
 
Triglyceride elevations in type 2 diabetes may also be due to delayed clearance 
of postprandial particles. 
34 
 
Alterations in Low- Density Lipoprotein Cholesterol 
 
Studies examining plasma concentrations of total and LDL cholesterol in type 
2 diabetes vary by population, with some showing higher and some showing 
lower levels in type 2 diabetes than in control subjects.
36 
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Metabolic Determinant 
3, 37 
 
The composition of LDL in type 2 diabetes is altered, with an increase in the 
proportion of small, dense, triglyceride-enriched LDL and these changes also 
contribute significantly to abnormal metabolism and atherosclerosis. The small, 
dense LDL have increased oxidative susceptibility and are more rapidly 
oxidized. Oxidized LDL particles are believed to play a major role in 
stimulating the atherosclerotic process because of their recognition by 
macrophage receptors. 
 
Increased plasma triglyceride levels, low HDL levels, and small, dense LDLs 
usually occur together in a lipoprotein pattern often referred to as atherogenic 
dyslipidemia. 
 
The transfer of LCAT-synthesized cholesteryl esters to VLDL and LDL is 
inhibited, with a concomitant increase in their transfer to HDL; this abnormal 
metabolic pattern is reversed by insulin therapy. The block in cholesteryl ester 
transfer activity in patients with type 2 diabetes is correlated with an increase in 
free cholesterol content of both LDL and VLDL. Therefore, in type 2 diabetes, 
this abnormal cholesteryl ester transfer may be related to an increased risk for 
atherosclerosis. 
 
47 
 
Alterations in High-Density Lipoprotein Cholesterol 
In individuals with type 2 diabetes decreased concentrations of HDL 
cholesterol has been observed. 
3 
 
Metabolic Determinant 
Individuals with type 2 diabetes have an increased rate of HDL clearance. 
Elevated hepatic lipase activity also contribute to the decrease in HDL 
concentrations in type 2 diabetes. 
38
 
In type 2 diabetes an increased proportion of triglyceride in HDL has been 
observed. These compositional changes appear to be related to the activity of 
adipose tissue LPL, because LPL deficiency may be a factor responsible for the 
altered distribution of HDL particles in untreated type 2 diabetes. Nonenzymatic 
glycation of HDL appears to interfere with HDL receptor binding.
39 
 Thus, 
glycation of HDL may also play a role in the lower levels of HDL observed in 
diabetes. Finally, abnormalities in HDL composition have been noted even in 
individuals with optimal glycemic control. 
40
   
All of these alterations in HDL composition may impair the role of HDL in 
reverse cholesterol transport. 
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                                      DIABETIC DYSLIPIDEMIA 
 
The dyslipidemia associated with type 2 diabetes and insulin resistance typically 
consists of elevated triglycerides and decreased HDL cholesterol level. The 
frequently mild abnormality in LDL cholesterol concentration associated with 
diabetes belies a qualitative abnormality in the LDL structure, i.e., decreased 
size and increased density of the LDL particle.
 41
 LDL appears to be a very 
potent contributor to the development of CHD  
 
Unlike LDL-C, which is well-established as a major predictor for CVD in 
global populations, the independent relationship of TG on predicting CVD 
has long been controversial. 
42
  
 
Although some previous studies like UKPDS did not favour 
hypertriglyceridemia as an independent risk factor for CVD, two recent 
metaanalysis studies have suggested that TG is independently associated with 
myocardial infarction, CHD, CVD and CVD death. 
43, 44, 45, 46
  
 
Asian studies have shown that increased serum TG levels have been an 
independent risk factor for CHD and TG appeared to play an important role in 
the development of CHD. 
47, 48  
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The Copenhagen city heart study has shown significant increase in the hazard 
ratio with increasing non fasting triglycerides level 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 : Copenhagen heart study result 
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RATIONALE FOR THERAPY FOR LIPID ABNORMALITIES IN 
DIABETES 
 
Atherosclerotic macrovascular disease is the leading cause of morbidity and 
mortality in patients with diabetes mellitus. Both men and women with diabetes 
have a significantly increased risk of myocardial infarction (MI), stroke, and 
peripheral gangrene.
49, 50 
 The risk for developing coronary heart disease (CHD) 
begins prior to the development of type 2 diabetes. By the time the diagnosis of 
type 2 diabetes is made, more than half of all diabetic individuals already have 
clinical CHD.
51 
 In addition, patients with diabetes have an increased rate of MI-
associated pre hospital mortality, as well as increased morbidity and mortality 
during and after hospitalization. 
52
 
 
These data provide a strong rationale for treating cardiovascular risk factors in 
diabetic patients as aggressively as in nondiabetic patients with clinical CHD. 
Thus, diabetes confers a risk that is equivalent to that of known CHD. The ADA 
and the American Heart Association consider type 2 diabetes a CHD 
equivalent.
53 
 
Various Randomized controlled clinical trials demonstrate that people with 
diabetes benefit from cholesterol-lowering therapy, with improvements in 
lipoprotein values and reduced CVD events. 
51 
 
Table 3 : Results of Controlled Clinical Trials of Lipid Lowering in 
Individuals with Diabetes 
 
Study 
LDL HDL 
Triglycerides Clinical outcomes 
 
cholesterol cholesterol 
 
     
 
CARE 
33
 Decreased Increased Decreased 25% risk reduction (P = 0.05) 
 
 27% 5% 14%  
 
     
 
4S34,35 
Decreased Increased Decreased 55% risk reduction 
 
 36% 8% 10% (P = 0.002) 
 
    42% on later analysis 
 
    (P = 0.001) 
 
     
 
VA-HIT
36
 No change Increased Decreased 24% decrease in CVD death 
 
  6% 31% or nonfatal myocardial 
 
    infarction (P = 0.05) 
 
     
 
DAIS
37
 Decreased Increased Decreased 40% reduction in progression 
 
 10% 6% 29% of localized atherosclerotic 
 
    lesions (P = 0.02) 
 
     
 
AFCAPS/ Decreased Increased Decreased 33% reduction in CVD events 
 
TexCAPS
38
 25% 6% 15% (NS) 
 
     
 
HPS
39
 Decreased Increased Decreased 26% reduction in first CVD 
 
 29% 3% 14% event (data incomplete) 
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                        MATERIALS AND METHODS 
 
This was an observational study which included the patients admitted in The 
Government Mohan kumaramangalam Medical college Hospital, Tamil Nadu. 
 
The study included 50 patients with type 2 diabetes mellitus meeting the 
inclusion criteria and were compared with 50 age and sex matched healthy 
controls, fulfilling the inclusion and exclusion criteria. 
 
 
The study period : 
From August 2014 to July 2015 
 
 
INCLUSION CRITERIA 
Patients diagnosed with type 2 diabetes mellitus on the basis of revised 
American Diabetic Association Criteria (Fasting plasma glucose ≥126 mg/dl 
and 2 hour postprandial plasma glucose ≥200 mg/dl), aged more than 30 years. 
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EXCLUSION CRITERIA 
• Type 1 diabetes mellitus 
• Inherited disorder of lipid metabolism  
• Liver disease  
• Endocrine diseases affecting lipids (hypothyroidism, cushing's 
   syndrome) 
• Renal disease 
• Smoking and 
• Patients on medication affecting lipid metabolism  
 
Method of collection of data 
A detailed proforma was filled up for each patient, which included age, sex, IP 
number, detailed history, past and personal history, medication history. A 
detailed clinical examination was done. Laboratory parameters including fasting 
and postprandial blood glucose, renal function tests, liver function tests, ECG 
and routine urine examination 
 
Fasting and Post prandial lipid profile which included serum total cholesterol, 
serum triglycerides, LDL cholesterol, HDL cholesterol and VLDL were 
estimated in all the cases and controls. Blood was collected from patients after 
an overnight (12-hour) fast and six-hour postprandial (after a standard meal) for 
lipid profile measurements. 
54 
 
Statistical Analysis 
 
The following statistical methods were employed 
1. Descriptive statistics 
2. T test – Independent samples  
3. T test pair samples 
4. Repeated measure ANOVA 
5. Product-moment correlation 
Using SPSS for windows 
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                                  RESULTS 
In this study, fasting and post prandial lipid profile was done in 50 patients 
with type 2 diabetes mellitus and was compared with the fasting and post 
prandial lipid profile in 50 healthy controls, age and sex matched. 
 
Table 4: Age distribution of the cases and controls 
Age 
Control Diabetic 
Total 
N % N % 
31 - 40 3 6 3 6 6 
41 - 50 11 22 11 22 22 
51 - 60 16 32 16 32 32 
61 - 70 20 40 20 40 40 
Total 50 100 50 100 100 
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Graph 1 : Showing the age distribution of the cases and controls 
 
 
In this study, the study group constituted cases between the age 31 to 70 years. 
The majority of cases and controls were in the age group of 61-70 years which 
constituted 40% of the total; followed by persons in the age group 51-60 years 
who constituted 32% of the total study. 
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             Table 5 : Sex wise distribution of the cases and controls 
 
 
 
 
 
 
 
 
 
Graph 2 : Showing the sex wise distribution of the cases and controls 
 
In this study, 60 percent were males and 40 percent were females, in both the 
groups. 
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Male Female
Sex 
Control Diabetic 
Total 
N % N % 
Male 30 60 30 
60 60 
Female 20 40 20 
40 40 
Total 50 100 50 100 100 
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Table 6 : Duration of diabetes among the study group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4, 8% 
14, 28% 
26, 52% 
6, 12% 
DM 
Newly detected
1 - 5
6 - 10
Above 10
DM 
Control Diabetic 
Total 
N % N % 
No Diabetes 50 100    
Newly detected   4 8 54 
1 - 5   14 28 14 
6 - 10   26 52 26 
Above 10   6 12 6 
Total 50 100 50 100 100 
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Graph 3 : Graph showing the duration of diabetes among the study group 
 
 
 
 
 
In this study 8% of the cases were newly detected type 2 diabetics, whereas 
28% of the cases had diabetes for 1 - 5 years, 52%  had diabetes for 6 – 10 years 
and 12 % had diabetes for more than 10 years. In the control group none of the 
patients had type 2 diabetes mellitus. 
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Table 7 : Duration of hypertension among the study group 
 
 
 
 
 
 
 
             
 
 
 
 
 
30, 60% 
7, 14% 
13, 26% 
HTN 
No HTN
1 - 5
Above 5
HTN 
Control Diabetic 
Total 
N % N % 
No HTN 50 100 30 60 80 
1 - 5   7 14 7 
Above 5   13 26 13 
Total 50 100 50 100 100 
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Graph 4 : Graph showing the duration of hypertension among 
the study group 
 
 
 
 
 
In this study, 40 % of diabetics had hypertension whereas 60 % of diabetics 
were normotensive. None of the controls, were found to have hypertension. 
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Table 8a : Fasting Total Cholesterol levels among the cases and controls 
 
TC _ Fasting 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 200 42 84 38 76 80 
3.85 0.146 201 - 240 7 14 6 12 13 
Above 240 1 2 6 12 7 
Total 50 100 50 100 100 
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Table 8b: Post prandial Total Cholesterol levels among the cases and 
controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
TC_ Post 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 200 43 86 37 74 80 
2.85 0.241 
201 - 240 6 12 9 18 15 
Above 240 1 2 4 8 5 
Total 50 100 50 100 100 
  
64 
 
Graph 5 : Fasting and post prandial Total Cholesterol levels among 
the cases and controls 
 
 
 
 
 
 
 
 
In this study, in the fasting state, 24% of cases had total cholesterol levels of 
>200 mg/dl as compared with the control group wherein 16% of them had total 
cholesterol of >200 mg/dl. 
In the post prandial state, 26% of cases had total cholesterol levels of >200 
mg/dl, but when compared with that of controls only 14% of them had total 
cholesterol levels of >200 mg/dl. 
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Table 9 : Comparison of the mean fasting and post prandial Total 
Cholesterol  levels among the cases and controls 
 
 
  TC 
Group N 
Fasting Post 
Mean SD t p Mean SD t p 
Control 50 163.78 36.29 
1.4 0.166 
165.42 35.36 
0.99 0.323 
Diabetic 50 176.36 52.43 173.3 43.56 
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Graph 6 : Comparison of the mean fasting and post prandial Total 
Cholesterol levels among the cases and controls 
 
 
 
 
 
In this study, the mean TC level in the cases was 176.36 ± 52.43 mg/dl in the 
fasting state and 173.3 ± 43.56 mg/dl in the post prandial state. The controls had 
a mean TC level of 163.78 ± 36.29 mg/dl in the fasting state and 165.42 ± 35.36 
mg/dl in the post prandial state. 
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   Table 10a: Fasting LDL-C levels among the cases and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDL-C Fasting 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 100 23 46 29 58 52 
3.96 0.266 
101 - 130 17 34 11 22 28 
131 - 160 8 16 5 10 13 
161 - 190 2 4 5 10 7 
Total 50 100 50 100 100 
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Table 10 b: Post prandial LDL-C levels among the cases and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDL-C Post 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 100 23 46 26 52 49 
3.25 0.518 
101 - 130 17 34 12 24 29 
131 - 160 6 12 10 20 16 
161 - 190 3 6 2 4 5 
Total 50 100 50 100 100 
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Graph 7 : Fasting and post prandial LDL-C levels among the cases and 
controls 
 
 
 
 
 
In this study, in the fasting state, 58% of cases had LDL-C levels of <100 
mg/dl as compared with that of the control group where 46% of controls had 
LDL-C of <100 mg/dl. 
 
In the post prandial state, 52% of cases had LDL-C levels of <100 mg/dl as 
compared with that of control group where 46% of them had LDL-C of <100 
mg/dl. 
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Table 11: Comparison of the mean fasting and post prandial LDL-C levels 
among the cases and controls 
 
 
  LDL-C 
Group N 
Fasting Post 
Mean SD t p Mean SD t p 
Control 50 99.82 36.21 
0.18 0.857 
103.74 35.6 
0.88 0.383 
Diabetic 50 101.16 38.17 97.38 36.93 
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Graph 8 : Comparison of the mean fasting and post prandial LDL-C 
  levels among the cases and controls 
 
 
 
 
 
 
 
In this study, the cases had a mean LDL-C level of 101.16 ± 38.17 mg/dl in 
the fasting state and 97.38 ± 36.93 mg/dl in the post prandial state. The controls 
had a mean LDL-C level of 99.82 ± 36.21 mg/dl in the fasting state and 103.74 
± 35.6 in the post prandial state 
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Table 12 a: Fasting VLDL-C levels among the cases and controls 
 
 
 
 
 
 
 
 
 
 
VLDL-C Fasting 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 20 21 42 9 18 30 
10.76 0.029* 
21 - 40 25 50 27 54 52 
41 - 60 2 4 8 16 10 
61 - 80 2 4 5 10 7 
Above 100   1 2 1 
Total 50 100 50 100 100 
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 Table 12 b: Post prandial VLDL-C levels among the cases and controls 
 
 
VLDL-C Post 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 20 17 34 4 8 21 
18.42 0.001** 
21 - 40 26 52 23 46 49 
41 - 60 6 12 15 30 21 
61 - 80   6 12 6 
81 - 100 1 2 2 4 3 
Total 50 100 50 100 100 
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Graph 9 : Fasting and post prandial VLDL-C levels among the 
cases and controls 
 
 
 
 
 
 
 
 
 
In this study, in the fasting state 28% of cases had total VLDL-C levels of 
>40 mg/dl as compared with that of the control group where only 8% of them 
had VLDL-C levels of >40mg/dl. 
Similarly, in the post prandial state, 46% of cases had VLDL-C levels of >40 
mg/dl as compared with that of control group, where 14% of them had VLDL-C 
levels of >40 mg/dl. 
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Table 13 : Comparison of the mean fasting and post prandial VLDL-C 
levels among the cases and controls 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  VLDL-C 
Group N 
Fasting Post 
Mean SD t p Mean SD t p 
Control 50 26.2 13.41 
3.1 0.003 
28.12 14 
3.92 0.000 
Diabetic 50 36.76 20.01 41.58 19.82 
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Graph 10 : Comparison of the mean fasting and post prandial VLDL-C 
among the cases and controls 
 
 
 
 
 
 
In this study, the cases had a mean VLDL-C level of 36.76 ± 20.01 mg/dl in 
the fasting state and 41.58 ± 19.82 mg/dl in the post prandial state. The controls 
had a mean VLDL-C level of 26.2 ± 13.41 mg/dl in the fasting state and 28.12 ± 
14 mg/dl in the post prandial state. 
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Table 14a: Fasting Triglyceride levels among the cases and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TG Fasting 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 150 35 70 22 44 57 
9.70 0.021* 
151 - 200 12 24 15 30 27 
201 - 400 3 6 12 24 15 
Above 400   1 2 1 
Total 50 100 50 100 100 
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Table 14b: Post prandial Triglyceride levels among cases and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TG Post 
Control Diabetic 
Total 
Chi 
square 
p 
N % N % 
Up to 150 34 68 9 18 43 
28.02 < 0.001** 
151 - 200 11 22 19 38 30 
201 - 400 5 10 18 36 23 
Above 400   4 8 4 
Total 50 100 50 100 100 
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Graph 11 : Fasting and post prandial Triglyceride levels 
among the cases and controls 
 
 
 
 
 
 
 
In this study, in the fasting state 56% of the cases had total TG levels of >150 
mg/dl as compared with that of control group wherein only 30% of them had 
TG levels of >150 mg/dl. 
Similarly in the post prandial state, 82% of the cases had TG levels of >150 
mg/dl as compared with that of control group wherein only 32% of them had 
TG levels of >150 mg/dl. 
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Table 15 : Comparison of the mean fasting and post prandial triglyceride      
levels among the cases and controls 
 
 
 
  TG 
Group N 
Fasting Post 
Mean SD t p Mean SD t p 
Control 50 125.66 49.55 
3.7 0.000 
133.66 48.79 
6.03 0.000 
Diabetic 50 172.92 75.51 232.52 105.08 
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Graph 12 : Comparison of the mean fasting and post prandial Triglyceride 
levels among the cases and controls 
 
 
 
 
In this study, the cases had a mean TG level of 172.92.48 ± 75.51 mg/dl in the 
fasting state and 232.52 ± 105.08 mg/dl in the post prandial state. The controls 
had a mean TG level of 125.66 ± 49.55 mg/dl in the fasting state and 133.66 ± 
48.79 mg/dl in the post prandial state 
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Table 16a: Fasting HDL-C levels among the cases and controls 
 
 
HDL-C Fasting 
Diabetic Control 
Total 
Chi 
square 
p 
N % N % 
Up to 35 35 70 30 60 65 
3.00 0.223 36 - 45 11 22 10 20 21 
Above 45 4 8 10 20 14 
Total 50 100 50 100 100 
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Table 16b: Post prandial HDL-C levels among the cases and controls 
 
 
 
          
HDL-C Post 
Diabetic Control 
Total 
Chi 
square 
p 
N % N % 
Up to 35 40 80 29 58 64 
9.6 0.04 
36 - 45 9 18 15 30 26 
Above 45 1 2 6 12 10 
Total 50 100 50 100 100 
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Graph 13 : Fasting and post prandial HDL-C levels among the cases and 
controls 
 
 
 
 
 
 
 
 
In this study, in the fasting state 70% of the cases had HDL-C  levels of             
< 35 mg/dl as compared with that of control group wherein  60% of them had 
HDL-C  levels of  <35 mg/dl. 
Similarly in the post prandial state, 80% of the cases had HDL-C  levels of     
<35 mg/dl. as compared with that of control group wherein  58% of them had 
 HDL-C  levels of <35 mg/dl. 
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Table 17: Comparison of the mean fasting and post prandial HDL-C levels 
among the cases and controls 
 
 
  HDL-C 
Group N 
Fasting Post 
Mean SD p Mean SD p 
Diabetic 50 33.44 11.42 
0.316 
30.96 11.04 
0.04 
Control 50 35.8 11.99 33.14 11.15 
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Graph 14 : Comparison of the mean fasting and post prandial HDL-C 
levels among the cases and controls 
 
 
 
 
 
 
 
In this study, the cases had a mean HDL-C level of 33.44 ± 11.42 mg/dl in the 
fasting state and 30.96 ± 11.04 mg/dl in the post prandial state. The controls had 
a mean HDL-C level of 35.8 ± 11.99 mg/dl in the fasting state and 33.14 ± 
11.15 mg/dl in the post prandial state 
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DISCUSSION 
 
 
In the present study, fasting and post prandial lipid profile was done in 50 
patients with type 2 diabetes mellitus and was compared with the fasting and 
post prandial lipid profile in 50 healthy controls, age and sex matched, fulfilling 
the inclusion and exclusion criteria. 
 
Age distribution of cases and controls 
 
In the present study, the study group constituted cases from age 31 to 70 years. 
The majority of cases and controls were in the age group of 61-70 years which 
constituted 40% of the total; followed by persons in the age group 51-60 years 
who constituted 32% of the total study. The  mean age was 57.32 ± 9.13 years 
 
 
Sex wise distribution of the cases and controls 
 
In this study, 60% of the study group were males and 40% of the study group 
were females. Similarly the control group consisted of 60% males and 40% 
females age matched with  the study group 
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Duration of diabetes among the study group 
 
 
In this study 8% of the cases were newly detected with type 2 diabetes mellitus. 
The duration of diabetes in 28% of cases was between 1 - 5 years, 52% between 
6- 10 years and 12% of cases had diabetes for more than 10 years. In the control 
group none of the patients had diabetes.  
 
 
Prevalence of hypertension among the study group 
 
 
In the present study, the prevalence of hypertension among the cases was 40% 
and among the controls none of them had hypertension. 
In the study done by Sumesh raj et al 
54 
the prevalence of hypertension was 
seen to be significantly higher in the cases (28%), which is consistent with our 
study. 
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Comparison of the mean fasting and post prandial lipid levels among the 
cases and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group     N Mean   SD      p 
  
  
  
  
 F
A
S
T
IN
G
 
TC 
Control 50 163.78 36.29 
0.166 Diabetic 50 176.36 52.43 
HDL-C 
Control 50 35.80 11.42 
0.316 Diabetic 50 33.44 11.99 
LDL-C 
Control 50 99.82 36.21 
0.857 Diabetic 50 101.16 38.17 
VLDL-C 
Control 50 26.20 13.41 
0.003 Diabetic 50 36.76 20.01 
TG 
Control 50 125.66 49.55 
0.000 Diabetic 50 172.92 75.51 
 P
O
S
T
 P
R
A
N
D
IA
L
 
TC 
Control 50 165.42 35.36 
0.323 Diabetic 50 173.30 43.56 
HDL-C 
Control 50 33.14 11.04 
0.04 Diabetic 50 30.96 11.15 
LDL-C 
Control 50 103.74 35.60 
0.383 Diabetic 50 97.38 36.93 
VLDL-C 
Control 50 28.12 14.00 
0.000 Diabetic 50 41.58 19.82 
TG 
Control 50 133.66 48.79 
0.000 Diabetic 50 232.52 105.08 
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Total Cholesterol levels among the cases and controls 
 
 
In this study, in the fasting state, 24% of cases had total cholesterol levels of 
>200 mg/dl as compared with the controls where 16% of them had total 
cholesterol of >200 mg/dl. This association has a p value of 0.146, which is 
statistically not significant. Hence, the pattern of distribution of patients in 
different cholesterol levels was found to be similar in both  cases and controls. 
Similar observations were made in the studies done by SV Madhu et al.
55 
However, in the study done by Sumesh Raj et al
 54 
 it was found that diabetics 
had significantly higher levels of TC compared to the controls (p <0.05)
 
 
In this study, the cases had a mean TC level of 176.36 ± 52.43mg/dl in the 
fasting state and 176.72 ± 50.52 mg/dl in the post prandial state. The controls 
had a mean TC level of 163.78 ± 36.29 mg/dl in the fasting state and 165.42 ± 
35.36 mg/dl in the post prandial state. This association has a p value of 0.323, 
which is statistically  not significant. Hence, there was no significant increase in 
the post prandial TC level in the cases compared to that of the controls. Similar 
observations were made in the studies done by SV Madhu et al
 55
 wherein the 
cases had a mean TC level of 209.45 ± 40.27 mg/dl in the fasting state and peak 
mean TC level of 232.45 ± 53.13 mg/dl in the post prandial state. The controls 
had a mean TC level of 197.6 ± 57.13 mg/dl in the fasting state and peak mean 
TC level of 210.35 ± 54.31 mg/dl in the post prandial state 
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LDL-C levels among the cases and controls 
 
 
In this study, in the fasting state, 58% of cases had LDL-C levels of <100 
mg/dl as compared with that of the control group where 46% of controls had 
LDL-C of <100 mg/dl. This association has a p value of 0.266, which is 
statistically not  significant.  
This does not correlate with the study done by sumesh raj et al 
54
 and SV 
Madhu et al 
55
 which showed that LDL-C was higher in the diabetics than in the 
controls.  
In this study, the cases had a mean LDL-C level of 101.16 ± 38.17 mg/dl in 
the fasting state which is within the normal range. In the Strong Heart Study 
56 
done by Howard BV et al it was shown that, in American Indians, LDL 
cholesterol level was the most significant predictor of increased CHD, despite 
an average LDL cholesterol level of approximately 115 mg/dL in diabetics. In 
the same study, LDL was a strong predictor of CHD at levels as low as 70mg/dl 
 
In this study, the cases had a mean LDL-C level of 101.16 ± 38.17 mg/dl in 
the fasting state and 97.38 ± 36.93 mg/dl in the post prandial state. The controls 
had a mean LDL-C level of 99.82 ± 36.21 mg/dl in the fasting state and 103.74 
± 35.6 in the post prandial state. This association has a p value of 0.383. Hence, 
statistically insignificant. 
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 In our study though the diabetics had a decreased LDL-C in the post prandial 
state, it was statistically insignificant. This does not correlate with a study done 
by Lund et al
57
which showed that in diabetics, LDL-C decreased significantly 
post prandially (p < 0.005). 
 
 
 
VLDL-C levels among the cases and controls 
 
 
In this study, in the fasting state 28% of cases had total VLDL-C levels of 
>40 mg/dl as compared with that of the control group where only 8% of them 
had VLDL-C levels of >40mg/dl. This association has p value of 0.029 which is 
statistically significant. 
 
Thus cases with diabetes were found to have elevated VLDL-C levels when 
compared with that of controls. This correlates with the study done by Angela A 
Rivellese et al.
 58 
 
Similarly, in the post prandial state, 46% of cases had VLDL-C levels of >40 
mg/dl as compared with that of control group, where 14% of them had VLDL-C 
levels of >40 mg/dl. This association has a p value of 0.001 which is statistically 
significant. 
Thus cases with diabetes were found to have elevated post prandial VLDL-C 
levels when compared with that of controls . 
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In this study, the cases had a mean VLDL-C level of 36.76 ± 20.01 mg/dl in 
the fasting state and 41.58 ± 19.82 mg/dl in the post prandial state. The controls 
had a mean VLDL-C level of 26.2 ± 13.41 mg/dl in the fasting state and 28.12 ± 
14 mg/dl in the post prandial state. ).This association has a p value of 0.000 
which is statistically significant.  
 
Hence, there was significant increase in the post prandial VLDL-C levels in 
diabetics. This does not correlate with the study done by Angela A Rivellese et 
al.
58 
 
 
Triglyceride levels among the cases and controls 
 
 
In this study, in the fasting state 56% of the cases had total TG levels of >150 
mg/dl as compared with that of control group wherein only 30% of them had 
TG levels of >150 mg/dl. This association has a p value of 0.021, which is 
statistically significant. 
 
Thus in the fasting state cases with diabetes were found to have elevated 
triglyceride levels when compared with that of the controls. This correlates with 
the studies done by Sumesh raj et al 
54
, SV Madhu et al 
55
& Angela A Rivellese 
et al. 
58 
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In this study, the cases had a mean TG level of 172.92.48 ± 75.51 mg/dl in the 
fasting state and 232.52 ± 105.08 mg/dl in the post prandial state. The controls 
had a mean TG level of 125.66 ± 49.55 mg/dl in the fasting state and 133.66 ± 
48.79 mg/dl in the post prandial state. This association has a p value of 0.000. 
Hence, statistically significant. 
 
 
Hence, there was a significant increase in the post prandial TG level in the 
cases compared to that of the controls.  
 
Similar observations were made in the studies done by SV Madhu et al 
55 
wherein the cases had a mean TG level of 187.1 ± 63.45 mg/dl in the fasting 
state and peak mean TG level of 425.2 ± 204.47 mg/dl in the post prandial state. 
The controls had a mean TG level of 156.85 ± 76.57 mg/dl in the fasting state 
and peak mean TG level of 283.9 ± 116.94 mg/dl in the post prandial state 
Similar observations were also made in the studies done by Sumesh raj et al 
54 
(p < 0.01), & Angela A Rivellese et al. 
58 
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HDL-C levels among the cases and controls 
 
 
In this study, in the fasting state 70% of the cases had HDL-C  levels of             
< 35 mg/dl as compared with that of control group wherein  60% of them had 
HDL-C  levels of  <35 mg/dl. 
This association has a p value >0.05, which is not significant. Hence, there was 
no significant difference in the HDL-C levels in both the cases and controls in 
the fasting state. 
 
This correlates with the study done by sumesh raj et al
 
which showed no 
significant difference in the HDL-C levels in the diabetics and controls. This 
does not correlate with the study done by SV Madhu et al
58
whichshowed that 
diabetics had lower HDL-C levels compared to that of the controls. 
 
In this study, the cases had a mean HDL-C level of 33.44 ± 11.42 mg/dl in the 
fasting state and 30.96 ± 11.04 mg/dl in the post prandial state. The controls had 
a mean HDL-C level of 35.8 ± 11.99 mg/dl in the fasting state and 33.14 ± 
11.15 mg/dl in the post prandial state.  
 
This association has a p value of 0.04 for post prandial state which is 
statistically significant. Hence, there was a significant decrease in the post 
prandial  HDL-C level in the cases compared to that of the controls. 
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Similar observations were made in the studies done by SV Madhu et al
 55 
in 
which the cases had a mean HDL-C level of 35.15 ± 10.84 mg/dl in the fasting 
state and 28.05 ± 10.94 mg/dl in the post prandial state. The controls had a 
mean HDL-C level of 42.9 ± 14.11 mg/dl in the fasting state and 37.15 ± 13.52 
mg/dl in the postprandial state. 
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                                     CONCLUSION 
 
 
 
 The dyslipidemia of Type 2 DM is characterized mainly by raised 
triglyceride levels, raised VLDL-C Levels and decreased HDL-C 
levels. 
 
 
 In the post prandial state there was significant hyper-
triglyceridaemia and decreased HDL-C levels in diabetics when 
compared to that of the controls. 
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                                        SUMMARY 
 
 
 Type 2 diabetes mellitus is associated with the development of premature 
atherosclerosis and a higher cardiovascular morbidity and mortality. 
Diabetic dyslipidaemia is believed to play an important role in the 
pathogenesis of accelerated atherosclerosis in this condition. 
 
 The predominant lipid abnormalities seen in diabetes mellitus are an 
elevated serum triglyceride level and a low HDL-C level. 
 
 The majority of cases and controls in the study group were in the age 
group of 61-70 years 
  
 There was a high prevalence of hypertension(40%) among the diabetics. 
 
 There was no significant difference in the TC level in the cases compared 
to that of the controls in both the fasting and post prandial state. 
 
 There was a no significant increase in the LDL-C level among the cases  
      compared to that of the controls in both the fasting and post prandial state  
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 The cases with diabetes were found to have elevated VLDL-C levels 
when compared with that of controls in both fasting and post prandial 
state. 
 
 In the fasting state cases with diabetes were found to have elevated 
triglyceride levels when compared with that of controls. There was a 
significant increase in the post prandial TG level in patients with diabetes. 
 
 Though the HDL-C levels in diabetics was low, there was no significant 
difference in the HDL-C levels in both the cases and controls in the 
fasting state. In the post prandial state, there was a significant decrease in 
the HDL-C level in the cases compared to that of the controls. 
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PROFORMA 
 
Name of the patient  : 
Age     : 
Sex     : 
Address               : 
Occupation               : 
IP No    : 
Date of admission   : 
Date of examination   : 
Chief complaints  : 
History of presenting illness : 
Past history               : 
Yes No Duration 
Diabetes - 
Hypertension - 
Hypothyroidism - 
Chronic liver disease - 
CKD - 
Drug history    : 
Whether on any statins, oral contraceptive pills Yes / No 
Other drugs               : 
Personal history  : 
Family history   : 
 
 
General examination  : 
Pulse     : 
B P                : 
Height- weight- 
Pallor- 
Icterus- 
Cyanosis- 
Clubbing- 
Lymphadenopathy- 
Pedal edema- 
Markers of Atherosclerosis - 
CVS   : 
RS   : 
P/A   : 
CNS   : 
FUNDUS          : 
 
Investigations : 
Hb %- gm/dl 
TC - cells/cu.mm 
DC - N- L- E- M- B 
RBS- mg/dl 
FBS - mg/dl 
PPBS - mg/dl 
B.urea- mg/dl 
s.creat - mg/dl 
LFT 
T.Bil-  mg/dl                  SGOT- U/L 
D.Bil- mg/dl                   SGPT- U/L 
Alb -  gm/dl                   ALP- U/L       
 
URINE R/E: 
Albumin- 
Sugar - 
Microccopy - 
ECG 
LIPID PROFILE 
FASTING (mg/dl) 
Post prandial (mg/dl) 
Total cholestrol 
HDL 
LDL 
VLDL 
TRIGLYCERIDES 
 
 
 
 
 
 
 
 
MASTER CHART CONTROLS 
 
S NO NAME AGE SEX IP NO DM HTN RBS FASTING LIPID PROFILE (mg/dl) 
 
POST PRANDIAL       LIPID PROFILE (mg/dl) 
        
TC HDL-C LDL-C VLDL-C TG TC HDL-C LDL-C VLDL-C TG 
1 
MOHAMMED 
KHAN 50yrs MALE 98936 - - 103 181 34 126 19 98 177 31 124 20 103 
2 SHANKAR 69yrs MALE 101032 - - 100 167 33 59 74 171 188 35 71 81 180 
3 ELUMALAI 60yrs MALE 105314 - - 130 127 36 70 14 70 129 36 78 14 71 
4 SENTHIL 64yrs MALE 29823 - - 110 165 27 112 25 129 154 27 100 26 131 
5 KUPPAN 55yrs MALE 107126 - - 70 130 29 90 10 55 149 29 105 13 79 
6 RAMAR 67yrs MALE 28677 - - 105 218 65 136 16 81 220 65 137 18 90 
7 SELVARAJ 60yrs MALE 103064 - - 77 136 26 89 20 102 140 26 92 22 110 
8 PALANI 62yrs MALE 103028 - - 122 118 35 50 32 163 116 30 50 36 176 
9 CHANDRAN 48yrs MALE 29265 - - 138 205 40 137 27 136 200 38 134 28 140 
10 DURAISAMY 65yrs MALE 29243 - - 103 181 34 126 19 98 177 31 124 20 103 
11 ARUMUGAM 57yrs MALE 105028 - - 99 128 31 60 33 169 130 30 66 34 172 
12 JAYARAMAN 55yrs MALE 105138 - - 76 122 22 43 57 289 105 16 38 51 256 
13 SELVAN 60yrs MALE 105236 - - 111 227 29 166 26 130 209 27 140 40 207 
14 GANAPATHY 60yrs MALE 105210 - - 108 228 30 157 40 203 236 30 166 40 200 
15 ADHAVAN ELANGO 48yrs MALE 105250 - - 112 110 28 59 33 165 112 30 48 34 170 
16 VENGATACHALAM 60yrs MALE 105298 - - 115 146 32 95 17 88 133 32 81 18 92 
17 CHINNAN 57yrs MALE 105680 - - 79 172 24 111 37 185 149 23 76 49 195 
18 SENTHIL 43yrs MALE 29823 - - 99 124 19 75 29 147 128 28 70 30 150 
19 ARUNACHALAM 51yrs MALE 30223 - - 135 180 31 132 17 88 184 30 136 18 90 
20 CHINNAPPAN 70yrs MALE 107136 - - 88 188 30 122 34 174 180 30 114 36 180 
21 JAYAPAL 65yrs MALE 107184 - - 100 151 38 92 21 106 155 36 97 22 110 
22 RAVI 49yrs MALE 107188 - - 132 230 49 142 39 198 222 56 122 44 221 
23 RAJENDRAN 61yrs MALE 109112 - - 136 195 34 41 20 104 200 34 144 22 110 
24 ARUMUGAM 61yrs MALE 109132 - - 139 160 37 106 17 85 166 36 111 19 96 
25 KUPPAN 65yrs MALE 109318 - - 116 160 24 124 15 75 180 25 140 14 75 
26 MADHU 70yrs MALE 109332 - - 85 128 38 70 20 100 142 42 78 22 112 
27 RAJI 38yrs MALE 3100 - - 70 116 30 70 16 83 130 41 73 60 81 
28 RAMASAMY 55yrs MALE 3782 - - 109 182 28 132 21 108 176 30 119 26 133 
29 JAYARAM 63yrs MALE 4450 - - 138 138 30 92 16 87 133 30 86 17 89 
30 KRISHNASAMY 46yrs MALE 4596 - - 112 141 19 53 62 235 135 16 47 10 246 
31 SAROJINI 65yrs FEMALE 7810 - - 134 140 87 29 22 112 146 80 42 24 120 
32 UMA 38yrs FEMALE 7812 - - 125 213 26 105 20 104 220 26 172 22 110 
33 REVATHI 37yrs FEMALE 7866 - - 123 121 38 50 31 159 130 36 62 32 160 
34 CHINNAMMAL 68yrs FEMALE 8048 - - 132 104 55 38 9 49 128 50 66 12 63 
35 LAKSHMI 50yrs FEMALE 8768 - - 122 178 40 118 20 96 180 38 122 20 100 
36 MALLIGA 70yrs FEMALE 8810 - - 132 173 22 134 16 84 170 22 130 18 90 
37 SIVAGAMI 49yrs FEMALE 8836 - - 122 164 26 114 22 113 160 24 112 24 120 
38 CHITTAYEE 65yrs FEMALE 8948 - - 82 162 24 107 30 151 168 22 113 33 164 
39 VALARMATHI 55yrs FEMALE 8942 - - 101 182 29 127 24 122 180 26 130 24 120 
40 RAJESHWARI 45yrs FEMALE 9348 - - 110 164 38 102 24 123 168 37 105 26 128 
41 KUPPAYEE 52yrs FEMALE 10980 - - 131 176 42 110 23 115 180 40 116 24 120 
42 KANNAMMAL 64yrs FEMALE 10992 - - 96 140 25 90 23 118 146 24 96 26 132 
43 SHARADA 50yrs FEMALE 4058 - - 136 165 30 111 22 114 170 28 119 23 116 
44 BANUMATHI 68yrs FEMALE 13160 - - 99 108 24 65 17 89 110 24 68 18 90 
45 MYNAVATHI 60yrs FEMALE 3110 - - 133 259 32 187 39 195 264 30 192 42 210 
46 SOWRIYAMMAL 43yrs FEMALE 132927 - - 139 139 33 88 17 87 140 33 89 18 92 
47 MANJULA 58yrs FEMALE 13280 - - 124 161 38 113 10 47 164 36 114 14 70 
48 LAKSHMI 70yrs FEMALE 15282 - - 89 217 36 158 22 111 222 34 164 24 120 
49 SAVITHRI 60yrs FEMALE 15427 - - 113 174 30 86 57 189 170 30 80 60 200 
50 VIJAYA 65yrs FEMALE 16312 - - 136 195 35 122 36 183 200 34 128 38 190 
MASTER CHART CASES 
 
S NO NAME AGE SEX IP NO DM HTN RBS FASTING LIPID PROFILE (mg/dl) 
                                                                                      
 POST PRANDIAL LIPID PROFILE (mg/dl) 
        
TC HDL-C LDL-C VLDL-C TG TC HDL-C LDL-C VLDL-C TG 
1 VADIVEL 50 MALE 30959 5yrs 4yrs 120 203 55 120 18 93 209 52 134 23 129 
2 KANNAM 69 MALE 36926 10yrs - 295 284 62 101 120 260 256 52 131 73 369 
3 KUPPUSAMY 60 MALE 38876 10yrs 2yrs 315 317 77 182 28 144 188 52 107 28 198 
4 VELLAIYAN 64 MALE 39108 5yrs 5yrs 162 167 31 42 24 120 182 28 130 50 180 
5 NALLATHAMBI 55 MALE 32592 8yrs - 253 261 51 166 43 218 265 40 180 50 270 
6 JEYARAMAN 67 MALE 10893 20yrs 5yrs 172 191 30 129 32 160 137 30 74 33 165 
7 ARUMUGAM 60 MALE 33780 6yrs - 224 174 56 99 18 93 217 57 136 23 118 
8 NATESAN 62 MALE 37612 10yrs - 98 115 27 76 11 156 110 31 68 10 198 
9 MARIYAPPAN 48 MALE 37566 5yrs - 362 168 28 100 39 197 183 30 92 60 301 
10 GOPAL 65 MALE 30484 15yrs 6yrs 160 129 33 77 18 92 150 44 75 30 180 
11 MUTHUSAMY 57 MALE 32384 8yrs - 360 170 28 106 35 106 125 31 70 24 126 
12 USMAN 55 MALE 25742 8yrs - 172 110 26 93 65 108 93 28 44 30 148 
13 VAIYYAPURI 60 MALE 25886 9yrs - 223 224 42 153 28 141 221 40 127 53 267 
14 RAVIBALAN 60 MALE 26786 11yrs 4yrs 371 324 39 149 54 328 257 50 152 72 465 
15 CHANDIRAN 48 MALE 27860 10yrs 9yrs 143 196 35 85 76 412 232 10 112 82 622 
16 SANTHAN 60 MALE 31938 ND - 220 142 31 87 23 116 119 23 72 15 186 
17 JAYAVEL 57 MALE 32372 ND - 95 168 52 90 28 126 178 40 108 30 150 
18 BABUK 43 MALE 10963 4yrs - 108 141 46 79 15 79 139 44 70 24 123 
19 BOOPATHI 51 MALE 33844 2yrs - 176 130 31 56 42 214 138 25 61 52 260 
20 PERUMAL 65 MALE 37786 12yrs 6yrs 222 136 22 82 32 160 156 18 102 36 180 
 
21 KANNUGOUNDAR 70 MALE 98924 10yrs 6yrs 185 152 27 84 41 207 150 22 78 50 249 
22 KUMAR 49 MALE 98974 8yrs - 211 140 25 78 36 182 146 21 83 42 212 
23 NATESAN 61 MALE 10562 9yrs 9yrs 233 263 46 186 30 151 231 56 137 37 187 
24 PERUMAL 61 MALE 37932 7yrs - 107 184 36 119 28 143 198 30 134 34 170 
25 DHARMAPPAN 65 MALE 98965 11yrs 8yrs 232 142 42 60 40 200 128 43 43 42 230 
26 KANDASAMY 70 MALE 107204 8yrs - 215 170 47 87 36 187 175 42 75 59 296 
27 SUGUMAR 38 MALE 109044 3yrs - 300 186 44 71 70 351 189 41 50 97 486 
28 PATCHIYAPPAN 55 MALE 109218 9yrs - 422 152 28 82 41 206 151 31 21 48 282 
29 AYYAPERUMAL 63 MALE 3000 5yrs - 345 135 34 85 16 89 143 39 81 22 168 
30 GANESAN 46 MALE 10798 6yrs - 388 204 33 92 78 294 210 25 105 80 396 
31 KAMALA 65 FEMALE 42414 9yrs 6yrs 201 227 43 157 26 133 230 35 165 30 152 
32 ANARGALI 38 FEMALE 42548 ND - 177 248 34 176 38 190 245 24 139 80 402 
33 LAKSHMI 37 FEMALE 21910 1yr - 376 144 32 78 34 170 188 36 120 32 196 
34 SAMPOORNAM 68 FEMALE 21930 6yrs - 133 218 37 161 20 104 200 30 145 24 153 
35 JAYA 50 FEMALE 28140 4yrs - 253 150 24 95 30 151 148 23 82 41 208 
36 MUNIYAMMAL 70 FEMALE 9773 8yrs 4yrs 188 193 26 138 28 140 206 28 149 28 181 
37 RANGAMMAL 49 FEMALE 30168 6yrs 6yrs 256 197 50 120 25 128 182 44 109 27 186 
38 PALANIYAMMAL 65 FEMALE 30188 9yrs 6yrs 467 147 31 78 38 189 153 33 73 47 237 
39 KAMALA 55 FEMALE 34302 4yrs 2yrs 167 136 22 85 28 141 145 18 95 32 180 
40 PAAPATHI 45 FEMALE 6326 ND - 159 116 21 65 30 151 130 18 79 33 195 
41 SULOCHANA 52 FEMALE 1529 6yrs - 241 118 20 75 24 118 120 20 72 28 142 
42 SAMPAGAVALLI 64 FEMALE 7868 8yrs 6yrs 190 197 42 119 35 175 181 41 109 30 198 
43 NAGAMMAL 50 FEMALE 7978 4yrs - 309 159 35 102 24 110 160 39 89 27 137 
44 MADHAMMAL 68 FEMALE 8024 8yrs 6yrs 361 237 26 155 54 274 232 24 153 53 309 
45 CHELLAMMA 60 FEMALE 2231 5yrs - 99 102 30 54 20 80 110 26 64 20 156 
46 VASANTHA 43 FEMALE 11106 3yrs - 383 98 27 13 57 281 110 25 23 62 310 
47 THAMARAISELVI 58 FEMALE 13130 8yrs - 92 188 43 108 36 183 193 36 115 42 211 
48 SOWRIYAMMAL 70 FEMALE 13196 10yrs 8yrs 289 130 20 42 70 311 144 22 46 74 376 
49 CHINNAKKA 60 FEMALE 16498 12yrs 8yrs 172 161 20 105 42 213 145 20 80 44 260 
50 RAMAYEE 65 FEMALE 16448 4yrs - 100 174 43 116 14 71 167 40 110 16 126 
 
KEY TO MASTER CHART 
DM   :  Diabetes mellitus 
F   :  Female 
HDL-C  :  High density lipoprotein - cholesterol 
HTN   :  Hypertension 
LDL-C  :  Low density lipoprotein - cholesterol 
M   :  Male 
ND   :  Newly deteted 
RBS   :  Random blood sugar 
TC :    Total cholesterol 
TG   :  Triglycerides 
VLDL-C  :  Very low density lipoprotein - cholesterol 
 
 
